BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic firm specializing in the early detection of cancer, today announced the pricing for a subsequent offering of 2,222,222 units. Each unit comprises one ordinary share (or a pre-funded warrant as an alternative) and one Series A warrant, granting the right to purchase one and one-half ordinary shares. This offering is anticipated to generate gross proceeds of approximately $3.0 million. Each unit is being sold at an effective offering price of $1.35 per unit. The Series A warrants will be immediately exercisable at an exercise price of $1.35 per share and are set to expire five years from their issuance date.
Maxim Group LLC is serving as the exclusive placement agent for this offering. The transaction is projected to conclude on or about August 5, 2025, pending customary closing conditions.
The newly issued securities mentioned above are being offered pursuant to an amended registration statement on Form F-1 (File No. 333-289095) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on August 4, 2025. This offering is being made solely through a prospectus that forms part of the Registration Statement. A final prospectus related to the offering will be filed with the SEC. Copies of the final prospectus for this offering can be obtained from Maxim Group LLC, located at 300 Park Avenue, 16th Floor, New York, NY 10022, or by calling (212) 895-3745. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor will there be any sale of these securities in any state or other jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
For additional information, please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/
About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic solutions for life-threatening conditions that are ready for market. The Company’s leading product is ColoAlert®, an accurate, non-invasive, and user-friendly diagnostic test for the early detection of colorectal cancer, which is marketed throughout Europe. The Company is currently conducting a clinical study to prepare for its pivotal FDA clinical study and subsequent US regulatory approval. Mainz Biomed’s pipeline of product candidates also includes PancAlert, an early-stage pancreatic cancer screening test based on the real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” as defined by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” as well as other similar expressions that forecast or indicate future events or trends, or that are not statements of historical fact. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised when relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to achieve projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed periodically in other reports and public filings by the Company with the Securities and Exchange Commission (the “SEC”). Additional information concerning these and other factors that may affect the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are publicly available on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based solely on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
